ReviewNature reviews. Urology2020
Introducing PIONEER: a project to harness big data in prostate cancer research.
Review in Nature reviews. Urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- OMOP CDM Can Facilitate Data-Driven Studies for Cancer Prediction: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Big Tau: Structure, Evolutionary Divergence, and Emerging Roles in Cytoskeletal Dynamics and Tauopathies.Cells · 2026Review
- The evolution of radical prostatectomy: a scoping review on surgical techniques and integration of surgeon-assisting concepts into the surgical workflow.Frontiers in surgery · 2026Review
- PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research.Nature reviews. Urology · 2025Review
- An Overview of Patient-reported Outcomes for Men with Prostate Cancer: Results from the PIONEER Consortium.European urology open science · 2025Article
- The Innovative Health Initiative public-private partnership: a catalyst for big data-driven health research and innovation.Frontiers in medicine · 2025Article
- AGREE II Quality Assessment of National and International Clinical Practice Guidelines on Prostate Cancer Management by the OPTIMA Consortium.European urology open science · 2024Review
- Public Involvement and Engagement in Big Data Research: Scoping Review.Journal of participatory medicine · 2024Article
- Research protocol for an observational health data analysis to assess the applicability of randomized controlled trials focusing on newly diagnosed metastatic prostate cancer using real-world data: PIONEER IMI's "big data for better outcomes" program.International journal of surgery protocols · 2024Article
- Article
- Predictive Models for Assessing Patients' Response to Treatment in Metastatic Prostate Cancer: A Systematic Review.European urology open science · 2024Review
- Research Protocol for an Observational Health Data Analysis on the Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform.European urology open science · 2024Article
- Bioinformatics in urology - molecular characterization of pathophysiology and response to treatment.Nature reviews. Urology · 2024Review
- Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?European urology open science · 2024Article
- The arisal of data spaces: why I am excited and worried.Frontiers in immunology · 2024Article
- Baseline characteristics and clinical outcomes of prostate cancer patients on delayed palliative management: a PIONEER analysis based on big data.Central European journal of urology · 2024Article
- Transforming Estonian health data to the Observational Medical Outcomes Partnership (OMOP) Common Data Model: lessons learned.JAMIA open · 2023Article
- Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium.Nature reviews. Urology · 2023Review
- Literature analysis of artificial intelligence in biomedicine.Annals of translational medicine · 2022Review
- MicroRNA-15a promotes prostate cancer cell ferroptosis by inhibiting GPX4 expression.Oncology letters · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
47 authors at 20 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. Launched by the Innovative Medicines Initiative 2 and part of the Big Data for Better Outcomes Programme (BD4BO), the overarching goal of PIONEER is to provide high-quality evidence on prostate cancer management by unlocking the potential of big data. The project has identified critical evidence gaps in prostate cancer care, via a detailed prioritization exercise including all key stakeholders. By standardizing and integrating existing high-quality and multidisciplinary data sources from patients with prostate cancer across different stages of the disease, the resulting big data will be assembled into a single innovative data platform for research. Based on a unique set of methodologies, PIONEER aims to advance the field of prostate cancer care with a particular focus on improving prostate-cancer-related outcomes, health system efficiency by streamlining patient management, and the quality of health and social care delivered to all men with prostate cancer and their families worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.